EMA reports high percentage of late paediatric investigation plans
This article was originally published in SRA
Executive Summary
A report by the European Medicines Agency on the implementation of the EU Paediatric Regulation in 2010 has found that pharmaceutical companies are largely still not fulfilling their obligation to submit paediatric investigation plans, or apply for waivers, upon completing human pharmacokinetic studies in adults1,2.